181 related articles for article (PubMed ID: 35593402)
1. Metastatic pheochromocytomas and paragangliomas: where are we?
Prinzi N; Corti F; Torchio M; Niger M; Antista M; Pagani F; Beninato T; Pulice I; Rossi RE; Coppa J; Cascella T; Giacomelli L; Di Bartolomeo M; Milione M; de Braud F; Pusceddu S
Tumori; 2022 Dec; 108(6):526-540. PubMed ID: 35593402
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of systemic treatment according to germline mutational status in patients with metastatic pheochromocytoma and paraganglioma.
Park YG; Park I; Kim Y; Lee HS; Lee W; Yoon S; Lee JL
Clin Genitourin Cancer; 2024 Apr; 22(2):413-419. PubMed ID: 38228412
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies in Pheochromocytoma and Paraganglioma.
Wang K; Crona J; Beuschlein F; Grossman AB; Pacak K; Nölting S
J Clin Endocrinol Metab; 2022 Nov; 107(11):2963-2972. PubMed ID: 35973976
[TBL] [Abstract][Full Text] [Related]
4. Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures.
Wang K; Schütze I; Gulde S; Bechmann N; Richter S; Helm J; Lauseker M; Maurer J; Reul A; Spoettl G; Klink B; William D; Knösel T; Friemel J; Bihl M; Weber A; Fankhauser M; Schober L; Vetter D; Broglie Däppen M; Ziegler CG; Ullrich M; Pietzsch J; Bornstein SR; Lottspeich C; Kroiss M; Fassnacht M; Wenter VUJ; Ladurner R; Hantel C; Reincke M; Eisenhofer G; Grossman AB; Pacak K; Beuschlein F; Auernhammer CJ; Pellegata NS; Nölting S
Endocr Relat Cancer; 2022 May; 29(6):285-306. PubMed ID: 35324454
[TBL] [Abstract][Full Text] [Related]
5. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas.
Zhou Y; Cui Y; Zhang D; Tong A
J Clin Endocrinol Metab; 2023 Feb; 108(3):755-766. PubMed ID: 36383456
[TBL] [Abstract][Full Text] [Related]
7. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview.
De Filpo G; Maggi M; Mannelli M; Canu L
J Endocrinol Invest; 2021 Jan; 44(1):15-25. PubMed ID: 32602077
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients.
Hadoux J; Terroir M; Leboulleux S; Deschamps F; Al Ghuzlan A; Hescot S; Tselikas L; Borget I; Caramella C; Déandréis D; Goere D; De Baere T; Schlumberger M; Baudin E
Horm Cancer; 2017 Dec; 8(5-6):330-337. PubMed ID: 28748315
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma.
Karakaya S; Gunnesson L; Elias E; Martos-Salvo P; Robledo M; Nilsson O; Wängberg B; Abel F; Påhlman S; Muth A; Mohlin S
Sci Rep; 2023 Jul; 13(1):11588. PubMed ID: 37463949
[TBL] [Abstract][Full Text] [Related]
10. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
12. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.
Juhlin CC
Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytomas and paragangliomas.
Yen K; Lodish M
Curr Opin Pediatr; 2021 Aug; 33(4):430-435. PubMed ID: 34039901
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic approach of pheochromocytomas and paragangliomas].
Gómez RM; Hernaiz M; de Miguel V; Aparicio LS; Marín MJ; Lupi S; Barontini M;
Hipertens Riesgo Vasc; 2019; 36(1):34-43. PubMed ID: 30078655
[TBL] [Abstract][Full Text] [Related]
16. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
Khatami F; Mohammadamoli M; Tavangar SM
Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
[TBL] [Abstract][Full Text] [Related]
17. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.
Lowery AJ; Walsh S; McDermott EW; Prichard RS
Oncologist; 2013; 18(4):391-407. PubMed ID: 23576482
[TBL] [Abstract][Full Text] [Related]
18. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.
Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ
J Clin Endocrinol Metab; 2009 Jan; 94(1):5-9. PubMed ID: 19001511
[TBL] [Abstract][Full Text] [Related]
19. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
20. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
